Myocardial Blood Flow by PET and N-13 Ammonia During Regadenoson vs Adenosine Stress

• Status: Completed
• Trial end date: 2012-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Blockage of the heart arteries (coronary artery disease) can lead to angina (chest pain), heart attacks, heart failure, and/or death. Positron emission tomography (PET) stress myocardial perfusion imaging (MPI) is a powerful tool to help identify blockages in the coronary arteries. During the PET MPI test, a drug is given to mimic the effects of exercise on the heart. The study was done to measure blood flow to the heart using two similar drugs approved to mimic the effects of exercise on the heart in people during a heart stress test. The first drug, called adenosine, has been approved for this use for several decades. The second drug, called regadenoson, was approved in 2008. The investigators were looking at whether the increase in blood flow to the heart with the newer drug (regadenoson) was similar to the increase in blood flow with the older drug (adenosine). This information is important for the use of these drugs in patients and for interpreting the blood flow values.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Mayo Clinic
• Collaborator: Astellas Pharma Inc
• Treatments: Adenosine; Regadenoson

Criteria

Inclusion Criteria:

• Healthy male and female volunteers over the age of 30.

• Written informed consent will be obtained from each subject.

• Each subject will undergo a history and physical examination

Exclusion Criteria:

• Any cardiovascular or pulmonary symptoms or exam findings

• History of low blood pressure (< 90/50 mmHg)

• Prior cardiac history

• History of hypertension

• History of hyperlipidemia

• History of diabetes mellitus

• History of asthma or chronic obstructive pulmonary disease

• Weight of > 450 pounds

• Chronic kidney disease

• Other serious illness such as cancer

• Current smoking

• Medication use (with the exception of acetaminophen, aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), and thyroid hormone replacement)

• Illicit drug use

• Prior allergic reaction to adenosine, regadenoson, or aminophylline

• Pregnancy